Heparin Beats Bivalirudin in Primary PCI — Physician’s First Watch

Medical News |
July 8, 2014

Heparin Beats Bivalirudin in Primary PCI

By Larry Husten

Edited by David G. Fairchild, MD, MPH, and André Sofair, MD, MPH

Bivalirudin is associated with a higher rate of major adverse cardiac events than heparin in patients with myocardial infarction undergoing primary percutaneous coronary intervention, according to a Lancet study.

Roughly 1800 patients undergoing primary PCI were randomized to either heparin or bivalirudin. There was a significant increase in the primary efficacy outcome — a composite of death, stroke, reinfarction, or unplanned target lesion revascularization at 28 days — in the bivalirudin group, compared with the heparin group (8.7% vs. 5.7%). There was no significant difference in the incidence of major bleeding. The use of bailout glycoprotein (GP) IIb/IIIa inhibitors was similar in both groups, roughly 15%.

Editorialists write that the difference in findings between the HEAT-PPCI trial and earlier trials can be explained by several factors, including the lower use of GP IIb/IIIa inhibitor in conjunction with heparin in HEAT-PPCI, the use of higher doses of heparin in previous studies, and the greater use of radial access in HEAT-PPCI. The trial, they write, "provides strong evidence that bivalirudin alone compared with 70 U/kg of heparin alone (with infrequent bailout use of GP IIb/IIIA inhibitors in both arms), with radial access for STEMI percutaneous coronary intervention, seems to be inferior to heparin as administered in this trial."

Adapted from CardioExchange

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.